« Back to Farmacia Journal 2/2026

EFFECTS OF DENOSUMAB COMBINED WITH CALCITRIOL ON BONE METABOLISM AND REFRACTURE RATE IN ELDERLY PA-TIENTS WITH OSTEOPOROTIC VERTEBRAL COMPRESSION FRACTURES AFTER PERCUTANEOUS KYPHOPLASTY

SAI YU, ZEBING ZHANG, TAISHAN ZHU, ZEYU YE, LEMING LIAO *

Download Full Article PDF

This retrospective study evaluated the effects of denosumab combined with calcitriol on bone metabolism, vertebral recovery, and refracture risk in elderly patients with osteoporotic vertebral compression fractures (OVCF) after percutaneous kyphoplasty (PKP). A total of 152 patients were divided into a control group (calcitriol, n = 76) and an observation group (denosumab plus calcitriol, n = 76) for 12 months. Radiological parameters and bone metabolism markers were assessed preoperatively and up to 12 months postoperatively. The observation group showed significantly improved vertebral anterior height recovery (82.3 ± 6.1% vs. 73.5 ± 7.8%), better Cobb angle correction, and a lower cement leakage rate (7.89% vs. 14.47%). At 6 and 12 months, bone mineral density and formation markers (BGP, PⅠNP) were higher, while β-CTX levels were lower (p < 0.05). The refrac- ture rate was significantly reduced (5.26% vs. 17.11%) without differences in adverse reactions. Vertebral recovery correlated positively with bone formation markers and negatively with resorption markers. Denosumab combined with calcitriol improves bone metabolism, enhances vertebral restoration, and reduces refracture risk, demonstrating favorable efficacy and safety in elderly OVCF patients after PKP.